Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia

European Journal of Haematology

Volumn 68, Issue 6, 2002, Pages 397-399

  Bolaños Meade, Javier ^a,b   López Arvizu, Carmen ^a   Cobos, Everardo ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myelogenous leukaemia; Essential thrombocythaemia

Indexed keywords

CYTARABINE; DAUNORUBICIN; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; HUMAN; MALE; MYELOID METAPLASIA; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BONE MARROW TRANSPLANTATION; FATAL OUTCOME; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 0036620685     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02730.x     Document Type: Article

References (12)

1. RAZZAN M, TAMPONI G, SCHINCO P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999;78:539-543.
2. STERKERS Y, PREUDHOMME C, LAI JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
3. CERVANTES F, TASSIES D, SALGADO C, ROVIRA M, PEREIRA A, ROZMAN C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-127.
4. RANDI ML, FABRIS F, GIROLAMI A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000;37:379-385.
5. FINAZZI G, BARBUI T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392.
6. THIELE J, KVASNICKA HM, ZANKOVICH R, DIEHL V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001;80:160-165.
7. CHISTOLINI A, MAZZUCCONI MG, FERRARI A, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-540.
8. UOZUMI K, OHNO N, SHIMOTAKAHARA S, et al. Trisomy 8 in essential thrombocythemia in leukemic transformation. Cancer Genet Cytogenet 2000;116:84-86.
9. NAND S, STOCK W, GODWIN J, FISHER SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996;52:42-46.
10. CHARACHE S, TERRIN ML, MOORE RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
11. ANDERSSON PO, RIDELL B, WADENVIK H, KUTTI J. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol 2000;79:40-42.
12. GELLER SA, SHAPIRO E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982;77:353-356.